09-10-2012

The 43rd Prix Galien recognized Généthon for its innovative treatments of rare diseases using gene therapy and awarded it the prize in the category of "Medicines destined for rare diseases - cell therapy and gene therapy." Created in 1990 by a patient association, the AFM-Téléthon, and 90% ...

more

09-07-2012

Alain Schwenck, 51, has joined Genethon as Director of Genethon Bioprod, the new site for the production of clinical grade-gene therapy medicines for the treatment of rare diseases, created by AFM-Telethon. Mr. Schwenck is a seasoned expert in manufacturing of pharmaceutical products. He ...

more

24-05-2012

France Biotech in partnership with Ernst & Young, published for the 10th year running the 'Life Science Panorama', describing the industry's main trends for 2010/2011 in France and worldwide. This time, almost 200 French companies took part in the survey. The panorama highlights the maturity ...

more

19-01-2012

Fulvio Mavilio, PhD (aged 58), an international acknowledged expert and pioneer in gene therapy for rare diseases for more than twenty years, was appointed as the new Scientific Director of Généthon (the not-for-profit biotherapy lab funded by the French Muscular Dystrophy Association (AFM) ...

more

16-01-2012

The results of a Phase I clinical trial of gene therapy for limb-girdle muscular dystrophy type 2C (a rare neuromuscular disease) have just been published in the journal Brain. The trial started in December 2006 and has been sponsored by Généthon (the not-for-profit research lab created by ...

more

24-11-2011

Cerenis Therapeutics announced the appointment of John F. Paolini, MD, PhD, FACC as Chief Medical Officer.Dr Paolini will be responsible for the strategic planning and execution of the clinical trials for Cerenis’ portfolio of novel cardiovascular therapies and, most importantly, Cerenis’ ...

more

07-10-2011

Mauna Kea Technologies announced that it has named medical device industry veteran Thierry Thaure Chief Executive Officer of its North American subsidiary. Former North American President Chris Tihansky will lead the company’s expansion efforts as Executive Vice President, Corporate ...

more

14-09-2011

BioAlliance Pharma SA announced preliminary phase I clinical results with its AMEP® biotherapy developed in advanced or metastatic melanoma, an invasive skin cancer of bad prognosis. The objectives of this first phase I trial were to evaluate the safety of intratumoral electrotransfer of ...

more

28-04-2011

BioAlliance Pharma SA announced the extension of its ongoing clonidine Lauriad™ phase II clinical trial in chemoradiation therapy induced oral mucositis in patients with head and neck cancer to Germany and Spain. The expansion of the trial (currently ongoing in France) to two new countries ...

more

15-04-2011

BioVision has announced the winners of the 2011 BioVision Lilly Award in conjunction with TWAS, the academy of sciences for the developing world, during a special ceremony held during the 7th World Life Sciences Forum (Lyon, France). The 2011 Award recognized 4 young scientists, living and ...

more